22 July 2025
22 July 2025
Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.
Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.
The new investment will support the ongoing development of Biogen's late-stage clinical pipeline.
Quantum computing could revolutionise protein modelling by enabling simulations of molecular behaviour at atomic resolution.
Representing its eighth funding round since launching in 2004, the oversubscribed fund had originally targeted a $600m close.
The acquisition includes Ayvakit/Ayvakyt, a treatment for rare immunological diseases.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
